Isotretinoin - Cipher Pharmaceuticals
Alternative Names: Absorica; Absorica AG; ABSORICA LD; CIP-isotretinoin; Epuris; Isotretinoin - Cipher; Lisacne-CIP; Semi-liquid isotretinoin capsules - CipherLatest Information Update: 16 Jul 2026
At a glance
- Originator Cipher Pharmaceuticals
- Developer Andromaco; Cipher Pharmaceuticals; Sun Pharmaceutical Industries
- Class Anti-inflammatories; Antiacnes; Antineoplastics; Keratolytics; Retinoids; Skin disorder therapies; Small molecules
- Mechanism of Action Ornithine decarboxylase inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Acne
Most Recent Events
- 06 Jul 2026 Cipher Pharmaceuticals signs Letter of Intent with the pan-Canadian Pharmaceutical Alliance (pCPA) for public drug plan coverage of Isotretinoin
- 04 Dec 2023 Launched for Acne in Canada (PO, Capsule micronized formulation)
- 26 Jun 2023 Health Canada approves Isotretinoin for Acne in Canada (PO, Capsule micronized formulation)